Medtronic PLC (2M6.BE)
| Previous close | 78.42 |
| Open | 79.74 |
| Bid | 76.66 x 0 |
| Ask | 76.73 x 0 |
| Day's range | 79.74 - 79.74 |
| 52-week range | 65.74 - 82.50 |
| Volume | |
| Avg. volume | 1 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Medtronic reports full year and fourth quarter fiscal 2024 financial results; announces dividend increase
Medtronic plc (NYSE:MDT) today announced financial results for its fourth quarter (Q4) and fiscal year 2024 (FY24), which ended April 26, 2024.
- PR Newswire
MiniMed™ 780G system recognized among Fast Company's 2024 World Changing Ideas
Fast Company announced that the Medtronic MiniMed™ 780G automated insulin delivery system has been recognized in the Best World-Changing Idea, North America category as part of the 2024 World Changing Ideas Awards.
- PR Newswire
EuroPCR: Medtronic Evolut™ TAVR Platform Demonstrates Improved Quality of Life for Women with Severe Aortic Stenosis
Medtronic, the global leader in healthcare technology, today announced new data from the largest head-to-head comparative trial of transfemoral transcatheter aortic valve replacement (TAVR), the SMall Annuli Randomized To Evolut or SAPIEN (SMART) Trial, looking exclusively at women. The findings showed the Evolut self-expanding valve (SEV) was associated with significantly less bioprosthetic valve dysfunction (BVD) and improved quality of life for women with symptomatic severe aortic stenosis (A
